Iraj Bijan, Moravejolahkami Amir Reza, Sami Ramin, Riahinezhad Maryam, Tasdighi Zahra, Toghyani Arash, Hosseini Nastaran Sadat, Niri Fatemeh Dehghan, Askari Gholamreza
Department of Internal Medicine, School of Medicine, Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Clinical Nutrition, School of Nutrition & Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Med Sci. 2023 Mar 16;28:15. doi: 10.4103/jrms.jrms_373_22. eCollection 2023.
Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEinhs) may deteriorate or improve the clinical manifestations in severe acute respiratory syndrome coronavirus 2 infection. A comparative, cross-sectional study was conducted to evaluate the association of ARBs/ACEinhs and hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (HMGRis) with clinical outcomes in coronavirus disease 2019 (COVID-19).
From April 4 to June 2, 2020, 659 patients were categorized according to whether they were taking ARB, ACEinh, or HMGRi drugs or none of them. Demographic variables, clinical and laboratory tests, chest computed tomography findings, and intensive care unit-related data were analyzed and compared between the groups.
The ARB, ACEinh, and HMGRi groups significantly had lower heart rate ( < 0.05). Furthermore, a lower percent of O saturation (89.34 ± 7.17% vs. 84.25 ± 7.00%; = 0.04) was observed in the ACEis group than non-ACEinhs. Mortality rate and the number of intubated patients were lower in patients taking ARBs, ACEinhs, and HMGRis, although these differences failed to reach statistical significance.
Our findings present clinical data on the association between ARBs, ACEinhs, and HMGRis and outcomes in hospitalized, hypertensive COVID-19 patients, implying that ARBs/ACEinhs are not associated with the severity or mortality of COVID-19 in such patients.
血管紧张素II受体阻滞剂（ARBs）和血管紧张素转换酶抑制剂（ACEinhs）可能会使严重急性呼吸综合征冠状病毒2感染的临床表现恶化或改善。开展了一项比较性横断面研究，以评估ARBs/ACEinhs和羟甲基戊二酰辅酶A还原酶抑制剂（HMGRis）与2019冠状病毒病（COVID-19）临床结局之间的关联。
2020年4月4日至6月2日，根据659例患者是否服用ARB、ACEinh或HMGRi药物，或未服用任何此类药物进行分类。分析并比较了各组之间的人口统计学变量、临床和实验室检查、胸部计算机断层扫描结果以及重症监护病房相关数据。
ARB、ACEinh和HMGRi组的心率显著较低（<0.05）。此外，ACEis组的氧饱和度百分比低于未服用ACEinhs的组（89.34±7.17%对84.25±7.00%；P = 0.04）。服用ARB、ACEinh和HMGRi的患者死亡率和插管患者数量较低，尽管这些差异未达到统计学显著性。
我们的研究结果提供了关于ARBs、ACEinhs和HMGRis与住院的高血压COVID-19患者结局之间关联的临床数据，这意味着ARBs/ACEinhs与这类患者的COVID-19严重程度或死亡率无关。
